European Medicines Agency

Doc. Ref. EMEA/583696/2009
P/190/2009

EUROPEAN MEDICINES AGENCY DECISION

of 22 September 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for clopidogrel (Clopidogrel BMS) (EMEA-000618-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

DISCLAIMER: This Decision does not entitle to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006, as amended.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 22 September 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for clopidogrel (Clopidogrel BMS) (EMEA-000618-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Bristol-Myers Squibb Pharma EEIG on 22 May 2009 under Article 16(1) of Regulation (EC) No 1901/2006 as amended also requesting a waiver under Article 13 of said Regulation,

Having regard to the Opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 August 2009, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended, and Article 13 of said Regulation and of its own motion in accordance with Article 21 of said Regulation**,**

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver,

(2) It is therefore appropriate to adopt a Decision agreeing a Paediatric Investigation Plan.

(3) It is therefore appropriate to adopt a Decision granting a deferral.

(4) It is therefore appropriate to adopt a Decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for clopidogrel (Clopidogrel BMS), age appropriate oral formulation, film-coated tablet, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for clopidogrel (Clopidogrel BMS), age appropriate oral formulation, film-coated tablet, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for clopidogrel (Clopidogrel BMS), age appropriate oral formulation, film-coated tablet, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, UB8 1DH, Uxbridge, United Kingdom.

Done at London, 22 September 2009

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Doc. Ref. EMEA/PDCO/440653/2009
EMEA-000618-PIP01-09

OPINION OF THE PAEDIATRIC COMMITTEE ON THE AGREEMENT OF A PAEDIATRIC INVESTIGATION PLAN AND A WAIVER

Scope of the application

Active substance(s):
Clopidogrel

(Invented) name:
Clopidogrel BMS

Condition(s):
Thromboembolic events

Pharmaceutical form(s):
Age appropriate oral formulation
Film-coated tablet

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
Bristol-Myers Squibb Pharma EEIG

Information about the authorised medicinal product: see Annex II

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb Pharma EEIG submitted for agreement to the EMEA on 22 May 2009 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 25 June 2009.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral on its own motion in accordance with Article 21 of said Regulation,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Norwegian Paediatric Committee member does agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex(es) and appendix(ces).

London, 21 August 2009

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S)

Thromboembolic events

B. WAIVER

- **Condition**

Atherothrombotic events

- **Subset(s) of the paediatric population, pharmaceutical form(s) and route(s) of administration covered**

The waiver applies to:

– Children aged 0 to less than 18 years for the film-coated tablet and the oral solution for oral use

C. PAEDIATRIC INVESTIGATION PLAN

- **Condition to be investigated**

Thromboembolic events

- **Paediatric investigation plan indication**

Prevention of thrombosis and thromboembolic events in children at risk

- **Subset(s) covered**

Children aged 0 to less than 18 years

- **Formulation(s)**

Age appropriate oral formulation
Film-coated tablet

- **Studies / Measures**

Area	Number of studies	Description
Quality	0	Not applicable
Non-clinical	0	Not applicable
Clinical	5	Open, cross-over, randomized, mono-centre bioequivalence study of the 75 mg tablet and 75 mg oral solution of clopidogrel after single oral administration to young healthy men
		Multi-centre, randomised, double-blind, placebo-controlled dose-finding study and pharmacodynamic assessment of platelet aggregation inhibition with clopidogrel in neonates and infants at risk for thrombosis
		Randomised, multi-centre, double-blind, placebo-controlled efficacy and safety study of clopidogrel in neonates and infants with systemic-to-pulmonary artery shunt

		Double-blind extension phase of study #3 for children aged 1 year and older
		Open-label, non-comparative, pharmacodynamic, safety and descriptive efficacy study of clopidogrel in children at risk for thrombotic and / or thromboembolic events aged 2 to less than 18 years

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2014
Deferral for some or all studies contained in the paediatric investigation plan:	Yes

ANNEX II

INFORMATION ABOUT THE AUTHORISED MEDICINAL PRODUCT

EU Number	Invented name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Content (concentration)	Package size
EU/1/08/464/001	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)		14
EU/1/08/464/002	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (alu/alu)		14
EU/1/08/464/003	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)		28
EU/1/08/464/004	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (alu/alu)		28
EU/1/08/464/005	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)		30
EU/1/08/464/006	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (alu/alu)		30
EU/1/08/464/007	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)		50 x 1
EU/1/08/464/008	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (alu/alu)		50 x 1
EU/1/08/464/009	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)		84
EU/1/08/464/010	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (alu/alu)		84
EU/1/08/464/011	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)		90
EU/1/08/464/012	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (alu/alu)		90
EU/1/08/464/013	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)		100
EU/1/08/464/014	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (alu/alu)		100
EU/1/08/464/015	Clopidogrel BMS	300 mg	Film-coated tablet	Oral use	blister (alu/alu)		4 x 1
EU/1/08/464/016	Clopidogrel BMS	300 mg	Film-coated tablet	Oral use	blister (alu/alu)		30 x 1
EU/1/08/464/017	Clopidogrel BMS	300 mg	Film-coated tablet	Oral use	blister (alu/alu)		100 x 1
EU/1/08/464/018	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/Alu)		7
EU/1/08/464/019	Clopidogrel BMS	75 mg	Film-coated tablet	Oral use	blister (alu/alu)		7